Under construction – not a live service
Sign in
Taking peopleNo phase

Long-term follow-up of SKG0106 in people with wet age-related macular degeneration

Follows people with wet macular degeneration who already received SKG0106 for up to 5 years.

Plain-language title generated from the registry record
Registry title: A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Key facts

Where
Boston, Katy, and Norfolk, United StatesSee the 3 sites

Where in United States

  • Ophthalmic Consultants of BostonBoston, United StatesNot yet recruiting
  • Retina Consultants of TexasKaty, United StatesNot yet recruiting
  • Wagner Macula & Retina CenterNorfolk, United StatesNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Skyline Therapeutics
Trial code
NCT06346600
Record updated
1 September 2026
Original description
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.Read full original descriptionShow less

A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

Inclusion: Subjects who only meet all of the following criteria are eligible for this study:; nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study.

Exclusion: Subjects who are judged by the investigator unsuitable for this study.

ClinicalTrials.gov NCT06346600